Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-419-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.70 million
Profitability
Miscellaneous
Employees130
OptionableOptionable
Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions
What is Arbutus Biopharma's stock symbol?
Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma's earnings last quarter?
Arbutus Biopharma Corp (NASDAQ:ABUS) issued its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.13. The biopharmaceutical company earned $1.59 million during the quarter, compared to analyst estimates of $0.23 million. Arbutus Biopharma had a negative net margin of 1,116.69% and a negative return on equity of 91.36%. View Arbutus Biopharma's Earnings History.
When is Arbutus Biopharma's next earnings date?
What price target have analysts set for ABUS?
4 equities research analysts have issued 1-year price objectives for Arbutus Biopharma's stock. Their predictions range from $5.00 to $9.00. On average, they anticipate Arbutus Biopharma's stock price to reach $6.8333 in the next year. This suggests a possible upside of 85.2% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.
What is the consensus analysts' recommendation for Arbutus Biopharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arbutus Biopharma.
What are Wall Street analysts saying about Arbutus Biopharma stock?
Here are some recent quotes from research analysts about Arbutus Biopharma stock:
- 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (1/18/2019)
- 2. Chardan Capital analysts commented, "We maintain our BUY rating and are increasing our 12-month price target to $11.00: We continue to believe that Arbutus has the potential to become a significant competitor in the chronic hepatitis B virus (HBV) infection treatment market. We believe that future progress updates from its pipeline programs could serve as potential value creation events for the stock over the next 12-18 months. First up will be interim data in 2 study of the Company’s lead RNAi asset, ARB-1467, used as combination therapy for HBV. The Company’s second generation capsid assembly inhibitor, ARB-506, is now being evaluated in a Phase 1 study, which dosed its first patient yesterday, in an initial cohort of healthy human volunteers, and could report topline data by mid-2019." (7/16/2018)
Has Arbutus Biopharma been receiving favorable news coverage?
Media stories about ABUS stock have trended positive on Friday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arbutus Biopharma earned a news sentiment score of 2.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Arbutus Biopharma's key competitors?
Some companies that are related to Arbutus Biopharma include Apellis Pharmaceuticals (APLS), Lexicon Pharmaceuticals (LXRX), Inflarx (IFRX), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), Epizyme (EPZM), CytomX Therapeutics (CTMX), AC Immune (ACIU), Dynavax Technologies (DVAX), Radius Health (RDUS), ImmunoGen (IMGN), G1 Therapeutics (GTHX) and Intra-Cellular Therapies (ITCI).
Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the folowing people:
- Dr. Mark Joseph Murray, Pres, CEO & Director (Age 69)
- Dr. Michael J. Sofia, Chief Scientific Officer (Age 60)
- Dr. Elizabeth Howard, Exec. VP & Gen. Counsel (Age 64)
- Mr. Bruce G. Cousins, Consultant (Age 57)
- Mr. David C. Hastings, Chief Financial Officer (Age 57)
How do I buy shares of Arbutus Biopharma?
Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arbutus Biopharma's stock price today?
One share of ABUS stock can currently be purchased for approximately $3.69.
How big of a company is Arbutus Biopharma?
Arbutus Biopharma has a market capitalization of $215.81 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe.
What is Arbutus Biopharma's official website?
How can I contact Arbutus Biopharma?
Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]
MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
